FDA Brief

Warning letters Drugs

FDA warning letter to

Spa De Soleil, Inc.

High riskIssued Jul 8Posted Jul 14Center for Drug Evaluation and Research (CDER)

FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

What happened

FDA inspected Spa De Soleil's drug manufacturing facility in Sun Valley, CA, from January 20 to 26, 2026. FDA found significant CGMP violations, including inadequate investigations of 51 water out-of-limit/out-of-specification results from May 2024 through July 2025 and a water system with non-sanitary components, and said the company’s February 6, 2026 response was inadequate. FDA also found missing identity testing of incoming components, including high-risk components for methanol, DEG, or EG contamination, and inadequate process and lab method validation.

What FDA found

  1. Spa De Soleil did not adequately investigate 51 out-of-limit or out-of-specification water test results and used a water system with non-sanitary parts such as dead legs and threaded fittings.

    21 CFR 211.192
  2. The company did not test each incoming component lot for identity or verify supplier certificates of analysis, and it did not test high-risk components such as glycerin for DEG/EG or components at risk for methanol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company lacked adequate process validation and batch records did not include critical processing details or equipment identification.

    21 CFR 211.100(a)
  4. The company used an alternative microbiological test method without properly validating it as equivalent to USP methods.

    21 CFR 211.160(b)
  5. The quality unit did not effectively oversee contract labs, annual product reviews, or cleaning validation.

    21 CFR 211.22(a)

What FDA wants

FDA asks the company to correct the violations promptly and provide comprehensive remediation plans, risk assessments, and supporting data for its water system, component testing, process validation, lab methods, and quality unit. FDA specifically asks for DEG and EG test results from retained high-risk component lots, or retained finished product if needed, no later than 30 calendar days from the letter date.

Who should pay attention

  • brands that buy OTC topical drugs from this contract manufacturer
  • companies using glycerin or other high-risk components with supplier COAs only
  • quality teams responsible for water systems and component identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk